130 related articles for article (PubMed ID: 23032649)
1. Paradoxical reaction of raynaud phenomenon following the repeated administration of iloprost in a patient with diffuse cutaneous systemic sclerosis.
Barreira RI; García BB; López MG; Legazpi IR; Díaz HÁ; Penín IR
Ann Pharmacother; 2012 Oct; 46(10):e28. PubMed ID: 23032649
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
3. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
4. Iloprost treatment summer-suspension: effects on skin thermal properties and cytokine profile in systemic sclerosis patients.
Auriemma M; Vianale G; Reale M; Costantini E; Di Nicola M; Romani GL; Merla A; Muraro R; Amerio P
G Ital Dermatol Venereol; 2013 Apr; 148(2):209-16. PubMed ID: 23588147
[TBL] [Abstract][Full Text] [Related]
5. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W
Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013
[TBL] [Abstract][Full Text] [Related]
7. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
8. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
[TBL] [Abstract][Full Text] [Related]
10. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
Cordioli E; Virgilio S; Ghirardi R; Martinelli M
Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis.
Bertelle D; Bertoldo E; Bixio R; Rossini M
Scand J Rheumatol; 2023 Jan; 52(1):91-92. PubMed ID: 35723612
[No Abstract] [Full Text] [Related]
12. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
13. Is iloprost effective in secondary Raynaud's phenomenon?
Lustig N; Rada G
Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
[TBL] [Abstract][Full Text] [Related]
14. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
16. [Iloprost therapy in systemic sclerosis].
Bali G; Aberer E
Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
[TBL] [Abstract][Full Text] [Related]
17. Iloprost-induced sudden hearing loss.
Dursun E; Dogru S; Cincik H; Cekin E; Gungor A; Poyrazoglu E
J Laryngol Otol; 2007 Jun; 121(6):609-10. PubMed ID: 17359558
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
[TBL] [Abstract][Full Text] [Related]
19. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis.
Ceru S; Pancera P; Sansone S; Sfondrini G; Codella O; De Sandre G; Lechi A; Lunardi C
Clin Exp Rheumatol; 1997; 15(4):381-5. PubMed ID: 9272298
[TBL] [Abstract][Full Text] [Related]
20. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
[No Abstract] [Full Text] [Related]
[Next] [New Search]
